Retatrutide: Triple Agonist GLP-1/GIP/Glucagon
A next-generation triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously.
Quick Reference
| Research Dosage | 1-12mg weekly (clinical trial range) |
|---|---|
| Frequency | Once weekly |
| Administration | Subcutaneous injection |
| Half-Life | ~6 days (supports weekly dosing) |
| Reconstitution | 2mL bacteriostatic water per 10mg vial |
| Storage | Refrigerate after reconstitution, use within 4 weeks |
Retatrutide represents the cutting edge of incretin-based peptide research – a single molecule that activates three receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This "triple agonist" approach goes beyond the dual agonists like tirzepatide by adding glucagon receptor activation.
Developed by Eli Lilly (research code LY3437943), Retatrutide is currently in Phase 3 clinical trials. Early trial results have generated significant research interest, with published data showing effects exceeding those of existing single and dual agonists.
The addition of glucagon receptor agonism is the key innovation. While it might seem counterintuitive to activate a hormone that raises blood sugar, glucagon also powerfully increases energy expenditure and fat oxidation – effects that may enhance metabolic outcomes beyond what GLP-1/GIP alone achieve.
Research Applications
Triple Receptor Activation
Retatrutide's unique profile activates three receptor systems simultaneously:
GLP-1 Receptor
- Reduces appetite through hypothalamic signaling
- Slows gastric emptying
- Enhances insulin secretion (glucose-dependent)
- Established mechanism from semaglutide, liraglutide research
GIP Receptor
- Enhances insulin secretion
- May improve beta-cell function
- Adipose tissue effects
- Added to GLP-1 in tirzepatide; now combined with glucagon in retatrutide
Glucagon Receptor (The Novel Component)
- Increases energy expenditure
- Enhances fat oxidation and lipolysis
- Hepatic effects on glucose production
- The novel addition distinguishing retatrutide from dual agonists
Why Add Glucagon?
Glucagon receptor agonism provides:
- Increased resting energy expenditure (burn more calories)
- Enhanced lipolysis (fat breakdown)
- Hepatic glycogenolysis effects
- Thermogenic effects
- Potential for greater metabolic impact than GLP-1/GIP alone
Body Composition Research
Clinical trial data has shown significant effects:
- Published Phase 2 data demonstrated substantial weight reduction
- Effects exceeded those reported with dual agonists in head-to-head considerations
- Dose-dependent responses documented
- Changes in body composition studied via imaging
Glucose Metabolism Research
- GLP-1 and GIP both enhance glucose-dependent insulin release
- Improved glycemic control in diabetic populations studied
- HbA1c reductions documented in trials
- Glucagon component requires careful study in glucose homeostasis
Comparison: Single vs Dual vs Triple Agonists
| Property | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptors | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Agonist Type | Single | Dual | Triple |
| Approval Status | Approved | Approved | Phase 3 Trials |
| Developer | Novo Nordisk | Eli Lilly | Eli Lilly |
| Energy Expenditure | Minimal | Minimal | Increased (glucagon) |
| Fat Oxidation | Modest | Moderate | Enhanced (glucagon) |
| Frequency | Weekly | Weekly | Weekly |
Dosage Information
Clinical Trial Dosages
Phase 2 trials evaluated doses from 1mg to 12mg weekly:
- Lower doses: 1mg, 4mg weekly
- Mid-range: 8mg weekly
- Higher doses: 12mg weekly
Dose-dependent effects were observed across this range.
Titration Approach
Clinical protocols used gradual dose escalation:
- Start at lower doses
- Increase over weeks
- Allows GI adaptation
- Reduces initial side effects
Administration
Once-weekly subcutaneous injection. The ~6 day half-life supports this schedule.
Reconstitution Guide
Required Materials
- Retatrutide lyophilised powder
- Bacteriostatic water
- Sterile insulin syringe
- Alcohol swabs
Reconstitution Steps
- Allow the Retatrutide vial to reach room temperature before reconstitution
- Draw 2mL bacteriostatic water into the syringe
- Insert the needle into the vial and direct the stream of water down the inside wall of the vial – do not spray directly onto the powder
- Allow the powder to dissolve naturally without shaking. Retatrutide may take a few minutes to fully dissolve. Gentle swirling is acceptable.
- Store reconstituted solution refrigerated at 2-8°C immediately after reconstitution
Concentration Reference Table
| Vial Size | Water Added | Concentration | 4mg Dose | 8mg Dose |
|---|---|---|---|---|
| 10mg | 2mL | 5mg/mL | 0.8mL (80 units) | 1.6mL (160 units) |
| 10mg | 1mL | 10mg/mL | 0.4mL (40 units) | 0.8mL (80 units) |
Storage Guidelines
Lyophilised (Powder) Form
- Long-term storage: -20°C (freezer)
- Short-term storage: 2-8°C (refrigerator)
- Protect from light
- Stable as dry powder
Reconstituted Solution
- Must be refrigerated at 2-8°C
- Use within 4 weeks
- Do not freeze after reconstitution
- Protect from light
- Use sterile technique when drawing doses
Frequently Asked Questions
Common questions about Retatrutide research
What is Retatrutide?
Retatrutide is a triple receptor agonist peptide that activates GLP-1, GIP, and glucagon receptors simultaneously. Developed by Eli Lilly (LY3437943), it is currently in Phase 3 clinical trials. It represents the next evolution beyond single agonists (semaglutide) and dual agonists (tirzepatide).
What does "triple agonist" mean?
It means retatrutide activates three different receptor types: GLP-1 receptors (appetite, insulin), GIP receptors (insulin, metabolism), and glucagon receptors (energy expenditure, fat oxidation). Each receptor contributes different effects.
How is Retatrutide different from Tirzepatide?
Tirzepatide is a dual agonist (GLP-1 + GIP). Retatrutide adds glucagon receptor activation as a third mechanism. The glucagon component increases energy expenditure and fat oxidation – effects not present with GLP-1/GIP alone.
How is Retatrutide different from Semaglutide?
Semaglutide is a single GLP-1 agonist. Retatrutide activates three receptors instead of one, potentially providing enhanced effects through multiple complementary mechanisms.
Is Retatrutide approved?
No. Retatrutide is currently in Phase 3 clinical trials. It is not approved by any regulatory agency (FDA, TGA, EMA). Timeline for potential approval depends on trial results.
Why add glucagon if it raises blood sugar?
While glucagon does increase blood glucose, it also significantly increases energy expenditure and promotes fat oxidation. When balanced with GLP-1/GIP effects (which enhance insulin and control glucose), the net result may be metabolic benefits without glucose dysregulation. Clinical trials assess this balance.
What were the Phase 2 trial results?
Published Phase 2 results showed dose-dependent effects on body weight, with the highest doses showing substantial reductions. Full Phase 3 data will provide more comprehensive efficacy and safety information.
How often is Retatrutide administered?
Once weekly, based on its ~6 day half-life. This is consistent with other long-acting incretin peptides.
What side effects were seen in trials?
Like other GLP-1 pathway compounds, gastrointestinal effects (nausea, vomiting, diarrhea) were reported in trials, particularly during dose escalation. Detailed safety data will emerge from Phase 3 trials.
The Science: How Retatrutide Works
Triple Receptor Mechanism
1. GLP-1 Receptor Agonism
GLP-1 (glucagon-like peptide-1) receptor activation:
Central Effects:
- Hypothalamic appetite suppression
- Reduced food intake and cravings
- Increased satiety signaling
Peripheral Effects:
- Glucose-dependent insulin secretion (pancreatic beta cells)
- Slowed gastric emptying (delays nutrient absorption)
- Reduced glucagon secretion (in fed state)
Mechanism: G-protein coupled receptor (GPCR), cAMP signaling cascade. Well-characterized from GLP-1 agonist research.
2. GIP Receptor Agonism
GIP (glucose-dependent insulinotropic polypeptide) receptor activation:
Pancreatic Effects:
- Enhanced insulin secretion
- Beta-cell support
- Complementary to GLP-1 effects
Adipose Tissue Effects:
- Effects on fat storage and metabolism
- May influence where fat is deposited
- Active research area
Added Value: Dual GLP-1/GIP activation (as in tirzepatide) shows enhanced effects vs. GLP-1 alone, synergistic insulin response, and potentially improved tolerability.
3. Glucagon Receptor Agonism (The Novel Component)
Glucagon receptor activation – this is what distinguishes retatrutide:
Energy Expenditure:
- Increases basal metabolic rate
- Thermogenic effects
- Body burns more calories at rest
- Potentially significant for weight research
Lipolysis and Fat Oxidation:
- Promotes breakdown of stored fat
- Increases fatty acid oxidation
- Hepatic fat mobilization
- Shifts metabolism toward fat burning
Hepatic Effects:
- Glycogenolysis (glycogen breakdown)
- Gluconeogenesis stimulation
- Requires balancing with GLP-1/GIP insulin effects
Why Glucagon Matters
Traditional thinking avoided glucagon in metabolic therapy (it raises blood sugar). But glucagon also:
- Increases energy expenditure 10-15% in some studies
- Powerfully mobilizes fat stores
- Creates catabolic state favoring fat loss
- When balanced with GLP-1/GIP insulin effects, glucose may remain controlled while gaining metabolic benefits
Balancing Three Receptors
The challenge of triple agonism is achieving the right balance:
- Enough GLP-1/GIP for glucose control and appetite suppression
- Enough glucagon for energy expenditure benefits
- Not so much glucagon that glucose control is compromised
Retatrutide's structure was designed to achieve this balance.
Structural Features
Retatrutide is a peptide designed for:
- Long half-life (~6 days) enabling weekly dosing
- Balanced activity at all three receptors
- Resistance to DPP-4 degradation
- Albumin binding for extended duration
The exact sequence is proprietary to Eli Lilly, but it is based on modifications to achieve triple receptor activity with appropriate potency ratios.
Technical Specifications
| Systematic Name | Retatrutide |
|---|---|
| Other Names | Reta, LY3437943, LY-3437943, Triple G, Triple Agonist, GGG Agonist, Eli Lilly Triple Agonist |
| Amino Acid Count | Proprietary |
| Sequence | Proprietary (Eli Lilly) |
| Molecular Formula | Proprietary |
| Molecular Weight | Proprietary (large peptide) |
| CAS Number | N/A (investigational) |
| Isoelectric Point | N/A |
| Net Charge (pH 7) | N/A |
| Appearance | White to off-white lyophilised powder |
| Solubility | Freely soluble in water and aqueous buffers |
| Purity (PurposeLabs) | ≥99% (HPLC verified) |
| Storage (Lyophilised) | -20°C long-term, 2-8°C short-term |
| Storage (Reconstituted) | 2-8°C, use within 4-6 weeks |
Quality: Australian University Testing
Why Peptide Quality Matters
The research peptide market contains products of highly variable quality. Independent testing of products from various suppliers has revealed significant issues:
- Purity levels as low as 50% in products claiming "99% purity"
- Incorrect amino acid sequences (entirely wrong peptides)
- Truncated sequences (missing amino acids)
- Bacterial endotoxin contamination
- Oxidised or degraded peptides with reduced activity
Our Testing Protocol
Every batch of Retatrutide from PurposeLabs undergoes comprehensive testing at a leading proteomics laboratory based at an Australian university in Sydney – one of Australia's premier analytical facilities.
Confirms purity levels of ≥99%, identifies any impurities or degradation products.
Verifies exact molecular weight, confirms correct amino acid sequence.
Determines actual peptide content versus salt, moisture, and counter-ions.
Why Australian University Testing?
Our testing partner is an established, verifiable proteomics facility at a major Australian university, with published research credentials, transparent methodology, and no commercial conflict of interest. This contrasts with overseas "certificates of analysis" from unknown or unverifiable laboratories.
Shop Retatrutide
Australian university tested. 99%+ purity verified by HPLC and mass spectrometry. Fast shipping from Sydney.
| Product | Size | Price |
|---|
References
Key studies for researchers seeking primary literature:
- Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial." New England Journal of Medicine, 2023.
- Rosenstock J, et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA." Lancet, 2023.
- Eli Lilly Clinical Trial Registry. "A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight" (Phase 3). ClinicalTrials.gov.
- Finan B, et al. "A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents." Nature Medicine, 2015. (Foundational triagonist research)
Disclaimer
All products sold by PurposeLabs are intended for laboratory and research use only. They are not intended for human or animal consumption. The information provided is for educational purposes only and should not be construed as medical advice. Consult with qualified healthcare professionals for any health-related decisions.
Retatrutide is not approved by the TGA for therapeutic use in Australia. Products are sold strictly for research purposes in accordance with Australian regulations.